Hepatotoxins Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Hepatotoxins stocks.

Hepatotoxins Stocks Recent News

Date Stock Title
Apr 24 GILD Gilead Sciences Q1 Preview: HIV pipeline, FY24 guidance in focus
Apr 24 ATXI Why Teledyne Technologies Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Apr 24 ATXI Dow Dips Over 100 Points; Ribbon Communications Shares Spike Higher
Apr 24 SNY What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Apr 24 GILD What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Apr 23 SNY Sanofi reportedly lining up banks for consumer products spinoff
Apr 23 SNY Sanofi Asks Banks to Pitch for $20 Billion OTC Spinoff
Apr 23 SNY Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study
Apr 23 GILD Incyte (INCY) Earnings Expected to Grow: Should You Buy?
Apr 23 SNY Sanofi succeeds in late-stage trial for blood disorder candidate
Apr 23 GILD Gilead Q1 Earnings Preview: Most Gains Wiped Out - Cause For Concern?
Apr 23 SNY Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
Apr 22 HEPA S&P 500 Rises Over 1%; Zions Bancorp Shares Gain After Q1 Earnings
Apr 22 GILD Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
Apr 22 SNY Sanofi reportedly settles 4K Zantac cases for $100M
Apr 22 GILD Gilead Sciences: Some Signs Of An Impending Bottom
Apr 22 SNY Market Chatter: Sanofi to Pay More Than $100 Million to Settle 4,000 Suits Alleging Zantac Causes Cancer
Apr 22 GILD Insights Into Gilead (GILD) Q1: Wall Street Projections for Key Metrics
Apr 21 GILD Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Apr 21 SNY Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Hepatotoxins

Hepatotoxicity (from hepatic toxicity) implies chemical-driven liver damage. Drug-induced liver injury is a cause of acute and chronic liver disease.
The liver plays a central role in transforming and clearing chemicals and is susceptible to the toxicity from these agents. Certain medicinal agents, when taken in overdoses and sometimes even when introduced within therapeutic ranges, may injure the organ. Other chemical agents, such as those used in laboratories and industries, natural chemicals (e.g., microcystins) and herbal remedies can also induce hepatotoxicity. Chemicals that cause liver injury are called hepatotoxins.
More than 900 drugs have been implicated in causing liver injury (see LiverTox, external link, below) and it is the most common reason for a drug to be withdrawn from the market. Hepatotoxicity and drug-induced liver injury also account for a substantial number of compound failures, highlighting the need for toxicity prediction models (e.g. DTI), and drug screening assays, such as stem cell-derived hepatocyte-like cells, that are capable of detecting toxicity early in the drug development process. Chemicals often cause subclinical injury to the liver, which manifests only as abnormal liver enzyme tests.
Drug-induced liver injury is responsible for 5% of all hospital admissions and 50% of all acute liver failures.

Browse All Tags